Chafiq Hamdouchi, PhD
Phone: (317) 274-2810
950 W. Walnut St.
Indianapolis, IN 46202
- Senior Research Professor of Pathology & Laboratory Medicine, Department of Pathology and Laboratory Medicine, IU School of Medicine
- Co-Leader, Cancer Drug Discovery and Development
- Full member
, Experimental and Developmental Therapeutics
Dr. Hamdouchi is an accomplished scientific leader in drug discovery and development with extensive experience in advancing small molecules from target to clinical proof of concept. His areas of expertise include medicinal chemistry; oncology, diabetes, neuroscience and anti-infective research; strategic planning from target selection to clinical proof-of-concept; external collaborations in the U.S., Europe, and Asia; portfolio enablement and prioritization; mentoring and talent development.
Throughout his 23-year career at Eli Lilly & Co., he oversaw large global cross-functional drug discovery and development teams, championed the creation of multiple drug discovery strategies, and contributed to the discovery and development of a dozen clinical candidates, which encompassed novel treatments in cancer, diabetes, and infectious and neurodegenerative disease.
He also was the scientific leader responsible for Lilly’s external research and development strategy and successfully developed international drug discovery as an effective extension of Lilly’s global research capabilities. He established and led Lilly's first R&D outsourced team in Asia capable of executing a drug discovery process from target selection through clinical proof-of-concept, delivering four high quality clinical candidates.
After retiring from Lilly at the end of 2017, he joined Indiana University School of Medicine in 2018. He contributes to the advancement of the science of therapeutics discovery and translational medicine through research and educational programs. Part of his efforts is focused on building the underlying drug discovery and development capabilities of the IU Simon Comprehensive Cancer Center, implementing effective preclinical and clinical strategies to deliver a robust and diverse portfolio. He works at the interface of academic-industrial partnerships, building relationships, consulting, strategizing, negotiating, mentoring, and creating an effective collaborative research environment that stimulates the design and execution of target selection, lead generation, lead optimization, candidate selection, and Phase I and II clinical development. His strong leadership in the field is reflected in numerous patents, publications, invited lectures, and awards.